Clinical Trial Update: A Phase 2, Multicenter, Open-Label Trial to Evaluate Efficacy and Safety of Subcutaneous (SC) Mosunetuzumab in Previously Untreated Low Tumor Burden Follicular Lymphoma (LTB-FL). [Phase 2]

View source ↗

Summary

Phase 2, multicenter, open-label trial evaluating subcutaneous mosunetuzumab in previously untreated low tumor burden follicular lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• LUNSUMIO (mosunetuzumab)

Snippet

Sponsor: Tel-Aviv Sourasky Medical Center | Conditions: Follicular Lymphoma | Phase 2 | Status: NOT_YET_RECRUITING